Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer
This is a prospective, single-center, open, historically controlled real-world study.

The aims of this study is to evaluate the safety and effectiveness of Nab-paclitaxel combined with oxaliplatin and S-1 in the treatment of patients with advanced gastric cancer.
Gastric Cancer
DRUG: Nab-paclitaxel combined with oxaliplatin and S-1
AE, Number of participants with treatment-related adverse events as assessed by NCI-CTCAE V5.0, 2-year
Objective response rate (ORR), ORR is defined as the rate of complete response (CR) or partial response (PR), as determined by IRC using RECIST v1.1 criteria among patients with at least one target lesion., 7-month|Disease Control Rate (DCR), The proportion of all subjects who assessed the best overall curative effect as CR, PR, and disease stable (SD) according to the RECIST 1.1 standard., 7-month|Overall survival (OS), It is defined as the time from the first doses durg to the time of death due to any reason., 2-year
This is a prospective, single-center, open, historically controlled real-world study.

The aims of this study is to evaluate the safety and effectiveness of Nab-paclitaxel combined with oxaliplatin and S-1 in the treatment of patients with advanced gastric cancer.